Capital Bank & Trust’s Myriad Genetics MYGN Stock Holding History

Capital Bank & Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-300	Closed	-$9K	–	792
2019 Q3	$9K	Buy	+300	New	+$8.74K	﹤0.01%	562

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Capital Bank & Trust's MYGN Position: Q4 2019 in Review

Capital Bank & Trust sold out of Myriad Genetics (MYGN) in Q4 2019, closing a stake of 300 shares — an estimated $9K sold.

Capital Bank & Trust first reported a position in MYGN in Q3 2019 and held it in 1 quarter. The position peaked at $9K in Q3 2019. 227 funds tracked by Wall St. Rank hold MYGN as of Q4 2019.

Capital Bank & Trust reported no remaining Myriad Genetics position as of Q4 2019 after selling out during the quarter.
Capital Bank & Trust sold 300 Myriad Genetics shares in Q4 2019, an estimated $9K.
Capital Bank & Trust first reported a position in Myriad Genetics in Q3 2019 and held it in 1 quarter.
Capital Bank & Trust's Myriad Genetics position peaked at $9K in Q3 2019.
227 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2019.

Based on Capital Bank & Trust's 13F filing for Q4 2019, filed 18 Feb 2020.